Exacerbating Effects of Human Parvovirus B19 NS1 on Liver Fibrosis in NZB/W F1 Mice

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Hsu, Tsai Ching ^a,b,c,d   Tsai, Chun Chou ^a   Chiu, Chun Ching ^a,e   Hsu, Jeng Dong ^a,b   Tzang, Bor Show ^a,b,d  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

^e CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; NONSTRUCTURAL PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN VP1; PROTEIN VP2; RECOMBINANT PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENZYME ACTIVITY; FEMALE; HUMAN PARVOVIRUS B19; LIVER FIBROSIS; MOUSE; NONHUMAN; PARVOVIRUS INFECTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ACTINS; ANIMALS; COLLAGEN; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MICE; MICE, INBRED NZB; PARVOVIRUS B19, HUMAN; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

MUS; PARVOVIRUS;

EID: 84879513807     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068393     Document Type: Article

References (38)

1. Tsukada S, Parsons CJ, Rippe RA, (2006) Mechanisms of liver fibrosis. Clin Chim Acta 364: 33-60.
2. Friedman SL, (2000) Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275: 2247-2250.
3. Shek FW, Benyon RC, (2004) How can transforming growth factor beta be targeted usefully to combat liver fibrosis? Eur J Gastroenterol Hepatol 16: 123-126.
4. Heldin CH, Miyazono K, Ten Dijke P, (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-471.
5. Piek E, Westermark U, Kastemar M, Heldin CH, van Zoelen, et al. (1999) Expression of transforming- growth-factor (TGF)-beta receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-beta1. Int J Cancer 80: 756-763.
6. Xu R, Zhang Z, Wang FS, (2012) Liver fibrosis: mechanisms of immune-mediated liver injury. Cell Mol Immunol 9: 296-301.
7. Hahn BH (1993) An overview of the pathogenesis of systemic lupus erythematosus In: Wallace DJ, Hahn BH, Dubois' Lupus Erythematosus. Philadelphia: Williams and Wilkins. 69-76.
8. Mukai M, Bohgaki T, Notoya A, Kohno M, Tateno M, et al. (2000) Liver dysfunction due to apoptosis in a patient with systemic lupus erythematosus. 9: 74-77.
9. Abraham S, Begum S, Isenberg D, (2004) Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis 63: 123-129.
10. Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG, (2008) Liver involvement in systemic lupus erythematosus: case review of 40 patients. J Rheumatol 35: 2159-2164.
11. Mackay IK, Taft LI, Cowling DC, (1959) Lupoid hepatitis and the hepatic lesions of SLE. Lancet 1: 65-69.
12. Runyon BA, LaBrecque DR, Anuras S, (1980) The spectrumof liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med 69: 187-194.
13. Hsu TC, Chiang SY, Wu JH, Tsai CC, Huang CY, et al. (2008) Treatment with taurine attenuates hepatic apoptosis in NZB/W F1 mice fed with a high-cholesterol diet. J Agric Food Chem 56: 9685-9691.
14. Tzang BS, Chiang SY, Lai WX, Tsai CC, Wu JH, et al. (2008) Treatment with cystamine reduces apoptosis in liver from NZB/W F1 mice. Int Immunopharmacol 8: 589-596.
15. Hsu TC, Chen YC, Tsai CC, Wu JH, Li SL, et al. (2010) Protective effects of taurine against hepatic abnormality in NZB/W F1 mice fed a hypercholesterolemic diet. Food Chemistry 119: 62-68.
16. Young NS, Brown KE, (2004) Parvovirus B19. N Engl J Med 350: 586-597.
17. Landenberg P, Von Lehmann HW, Knöll A, Dorsch S, Modrow S, (2003) Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 48: 1939-1947.
18. Lehmann HW, von Landenberg P, Modrow S, (2003) Parvovirus B19 infection and autoimmune disease. Autoimmun Rev 2: 218-223.
19. Sève P, Ferry T, Koenig M, Cathebras P, Rousset H, et al. (2005) Lupus-like presentation of parvovirus B19 infection. Semin Arthritis Rheum 34: 642-648.
20. Hsu TC, Tzang BS, Huang CN, Lee YJ, Liu GY, et al. (2006) Increased expression and secretion of interleukin-6 in human parvovirus B19 non-structural protein (NS1) transfected COS-7 epithelial cells. Clin Exp Immunol 144: 152-157.
21. Tsai CC, Tzang BS, Chiang SY, Hsu GJ, Hsu TC, (2009) Increased expression of Matrix Metalloproteinase 9 in liver from NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein. J Biomed Sci 16: 14.
22. Tzang BS, Chen DY, Tsai CC, Chiang SY, Lin TM, et al. (2010) Human parvovirus B19 nonstructural protein NS1 enhanced the expression of cleavage of 70 kDa U1-snRNP autoantigen. J Biomed Sci 17: 40.
23. Chen DY, Tzang BS, Chen YM, Lan JL, Tsai CC, et al. (2010) The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome. Clin Chim Acta 411: 1084-1089.
24. Tzang BS, Lin TM, Tsai CC, Hsu JD, Yang LC, et al. (2011) Increased cardiac injury in NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein. Mol. Immunol 48: 1518-1524.
25. Tzang BS, Tsay GJ, Lee YJ, Li C, Sun YS, et al. (2007) The association of VP1 unique region protein in acute parvovirus B19 infection and anti-phospholipid antibody production. Clin Chim Acta 378: 59-65.
26. Tzang BS, Tsai CC, Tsay GJ, Wang M, Sun YS, et al. (2009) Anti-human parvovirus B19 nonstructural protein antibodies in patients with rheumatoid arthritis. Clin Chim Acta 405: 76-82.
27. Tsai CC, Chiu CC, Hsu JD, Hsu HS, Tzang BS, et al. (2013) Human parvovirus B19 NS1 protein aggravates liver injury in NZB/W F1 mice. PLoS ONE 2013;8(3): e59724 doi:10.1371/journal.pone.0059724.
28. Kajigaya S, Fujii H, Field A, Anderson S, Rosenfeld S, et al. (1991) Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci USA 88: 4646-4650.
29. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem 72: 248-254.
30. Towbin H, Staehelin T, Gordon J, (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications,. Proc Natl Acad Sci USA 76: 4350-4354.
31. Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, et al. (1994) Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 83: 262-267.
32. Marchesini G, Marzocchi R, Agostini F, Bugianesi E, (2005) Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16: 421-427.
33. Wieckowska A Papouchado BG, Li Z, Lopez R, Zein NN, et al. (2008) Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 103: 1372-1379.
34. Dixon JB, Bhathal PS, Jonsson JR, Dixon AF, Powell EE, et al. (2003) Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 39: 967-971.
35. Magro CM, Wusirika R, Frambach GE, Nuovo GJ, Ferri C, et al. (2006) Autoimmune-like pulmonary disease in association with parvovirus B19: a clinical, morphologic, and molecular study of 12 cases. Appl Immunohistochem Mol Morphol 14: 208-216.
36. Mitchell LA, (2002) Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections? J Med Virol 67: 267-274.
37. Fu Y, Ishii KK, Munakata Y, Saitoh T, Kaku M, et al. (2002) Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J Virol 76: 5395-5403.
38. Meijer C, Huysen V, Smeenk RT, Swaak AJ, (1993) Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus 2: 359-365.